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In the present study, we describe autologous blood coagulum (ABC) as a physiological
carrier for BMP6 to induce new bone formation. Recombinant human BMP6
(rhBMP6), dispersed within ABC and formed as an autologous bone graft substitute
(ABGS), was evaluated either with or without allograft bone particles (ALLO) in rat
subcutaneous implants and in a posterolateral lumbar fusion (PLF) model in rabbits.
ABGS induced endochondral bone differentiation in rat subcutaneous implants.
Coating ALLO by ABC significantly decreased the formation of multinucleated foreign
body giant cells (FBGCs) in implants, as compared with ALLO alone. However, addi-
tion of rhBMP6 to ABC/ALLO induced a robust endochondral bone formation with
little or no FBGCs in the implant. In rabbit PLF model, ABGS induced new bone for-
mation uniformly within the implant resulting in a complete fusion when placed
between two lumbar transverse processes in the posterolateral gutter with an opti-
mum dose of 100‐μg rhBMP6 per ml of ABC. ABGS containing ALLO also resulted
in a fusion where the ALLO was replaced by the newly formed bone via creeping sub-
stitution. Our findings demonstrate for the first time that rhBMP6, with ABC as a car-
rier, induced a robust bone formation with a complete spinal fusion in a rabbit PLF
model. RhBMP6 was effective at low doses with ABC serving as a physiological sub-
stratum providing a permissive environment by protecting against foreign body reac-
tion elicited by ALLO.
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Spinal fusion surgery is commonly performed in patients, where two or
more adjacent vertebral segments are fused to restrict motion primar-
ily to relieve the source of back and leg pain (Bohl et al., 2015; Diebo
et al., 2015; Gupta, Mohan, & Gupta, 2017; Mobbs, Loganathan,
Yeung, & Rao, 2013; Mobbs, Phan, Malham, Seex, & Rao, 2015). Auto-
grafts and allografts containing autologous bone marrow are routinely
employed to stimulate osteogenesis either at the intervertebral space
as in anterior lumbar interbody fusion (ALIF; Bohl et al., 2015) or at
an ectopic site between two lumbar transverse processes bilaterally
as in a posterolateral lumbar fusion (PLF; Liu, Wang, Qiu, Weng, &
Yu, 2014). A variety of disorders may be treated with spinal fusion,
including degenerative disc disease (DDD), spondylolisthesis, spinal
stenosis, scoliosis, infections, spinal fractures and dystrophy, and vari-
ous tumours (McAnany et al., 2016).
Autograft from the patient's posterior iliac crest bone is the “gold
standard” for spine fusion surgery as the harvested bone chips have
live bone marrow cells and an immunologically compatible extracellular
matrix (Garcia‐Gareta, Coathup, & Blunn, 2015; Goldberg & Steven-
son, 1987; Tilkeridis et al., 2014). However, the use of autograft pre-
sents several disadvantages: (a) It requires another incision that may
result in postoperative pain and an increased risk for infection and
(b) the amount of bone that can be harvested is limited (Fernyhough,
Schimandle, Weigel, Edwards, & Levine, 1992; Murphy et al., 2019).
As an alternative to autograft, several compositions are employed with
modest outcome that include allograft (cadaver bone from a bone
bank), demineralized bone matrix (Cahill, Chi, Day, & Claus, 2009;
Hsu, 2014), various ceramics (calcium‐based compounds) in conjunc-
tion with patients bone marrow (Carragee, Hurwitz, & Weiner, 2011),
and bone morphogenetic proteins (BMPs) in combination with animal
derived collagen (Simmonds et al., 2013) and/or with ceramic compos-
ite scaffolds (Brown et al., 2013).
Recombinant human BMP2 (rhBMP2) applied within an absorbable
collagen sponge (InFUSE) has been approved to treat DDD at one level
fusion (vertebra‐disc‐vertebra; ALIF) from L2 to S1 using Titanium LT
cages via an anterior (ALIF) and with polyetheretherketone (PEEK)
cages via lateral (oblique lateral interbody fusion) approach in skele-
tally mature patients (Carragee et al., 2011). An off‐label use of
INFUSE in related interbody fusion procedures (cervical) has resulted
in unwanted safety issues, presumably from the high rhBMP2 dose
employed (Brown et al., 2013; Hsu, 2014; Jain, Hassanzadeh, Strike,
Skolasky, & Riley, 2014; Riederman et al., 2017; Simmonds et al.,
2013). However, the clinical evaluation of rhBMP2 soaked in synthetic
ceramics (hydroxyapatite and tricalcium phosphate) and bovine‐
sourced collagen composite as a scaffold (Amplify) for the posterolat-
eral lumbar spinal fusion procedure (Glassman et al., 2008) has not
been approved by Food and Drug Administration for human use, in
part due to potential cancer risks in treated groups as compared with
autograft controls (Carragee et al., 2013) and posed numerous chal-
lenges including unwanted safety issues likely resulting from the high
dose of rhBMP2 employed (12–40 mg for a single‐level fusion; Brownet al., 2013; Cahill et al., 2009; Carragee et al., 2011; Fu et al., 2013;
Hsu, 2014; Simmonds et al., 2013; Vukicevic et al., 2014; Vukicevic
& Sampath, 2017). Similarly, rhBMP7 that contained bovine bone col-
lagen dispersed with additive carboxyl‐methyl cellulose (OP‐1 Putty)
has also failed to achieve successful outcome (Vaccaro et al., 2008).
These data suggest that use of low doses of a BMP with a natural bio-
compatible scaffold may provide a more permissive environment for
the optimal bone formation that is restricted to the implant site. Here,
we demonstrate that an autologous bone graft substitute (ABGS) that
contains a low dose of rhBMP6 that has a low affinity for the endog-
enous BMP antagonist, Noggin (abundant in bone; Song et al., 2010),
delivered with an autologous blood coagulum (ABC) carrier with or
without bone allograft particles (ALLO), is capable of inducing new
bone formation in rat subcutaneous implants and achieving a complete
fusion in rabbit PLF model.2 | MATERIALS AND METHODS
2.1 | Rat subcutaneous implant assay analyses
Rat subcutaneous assay was carried out to observe cellular events and
bone formation following subcutaneous implantation of allograft, ABC,
and rhBMP6 (Sampath & Reddi, 1981). Three types of implants (ALLO,
ABC + ALLO, and ABC + ALLO + rhBMP6) were composed and
implanted in the axillary region of male Sprague‐Dawley rats, aged
10 weeks. ABGS was prepared from 0.5 ml of rat blood, which was
mixed with 0.1 mg of allograft and 25 μg of rhBMP6 and left for 60
min to coagulate in a 1‐ml syringe. After removing the serum, the
ABGS was implanted. Two different experiments were performed
and implants were harvested on Days 1, 3, 7, and 14 in the first and
on Days 7 and 35 in the second experiment, with two rats and four
implants for each time point. Bone formation and cellular events were
analysed using micro‐CT and histology sections.2.2 | Rabbit model
Study protocols were conducted in 14‐week‐old male New Zealand
White laboratory rabbits (Oryctolagus cuniculus), New Zealand strain,
body weight 3–5 kg. The animal facility was registered by Directorate
for Veterinary, Reg. No: HR‐POK‐001. An approval for the animal
studies was given by the Directorate for Veterinary and Food Safety,
Ministry of Agriculture, Republic of Croatia (approval No. 525‐10/
0255‐14‐3). Laboratory animals were housed in standard rabbit cages
in conventional laboratory conditions at the temperature of 18–22°C,
relative humidity of 50–70%, fluorescent lighting provided illumination
12 hr/day and noise level 60 dB. Standard diet (Mucedola, Italy) bed-
ding with environmental enrichment were available, and fresh water
was provided ad libitum. Animal care was in compliance with standard
operating procedures of registries Croatian Animal facility HR‐POK‐
001; using 3R principle, minimization of the pain suffering during the
experiment; the European convention for the protection of vertebrate
animals used for experimental and other scientific purposes (ETS 123).
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ABGS without ALLO was produced by dispersing rhBMP6 into autolo-
gous blood, which then allowed to form coagulum with defined struc-
ture and rheological properties as determined by stiffness, elasticity,
and strain, testing as previously described (Grgurevic et al., 2018).
Blood samples were collected from rabbit marginal ear veins into tubes
without any anticoagulant substance, supplemented with 0.1 ml of 50‐
mM CaCl2 solution in a volume of 2.5 ml, 2 hr before surgery, and
lyophilized rhBMP6 (Genera Research, Croatia) was dissolved in water
for injection (c = 2.5 mg/ml) and mixed with blood in an appropriate
volume and then left in room temperature to coagulate. Allogenic
devitalized bone particles (ALLO) were prepared as described
(Tomford, 2000), and 70‐ to 420‐μm particle sizes were used to pro-
duce ABGS with allograft. To produce ABGS with ALLO, ALLO parti-
cles were added at 0.2 g/ml ABC/rhBMP6 mix and then left at room
temperature to coagulate. In biomechanical testing, amounts of 1,
1.5, and 2 g of ALLO per 5 ml of ABC/rhBMP6 were used.2.4 | PLF operation procedure
Twenty‐eight skeletally mature rabbits underwent bilateral posterior
intertransverse process fusion between lumbar vertebrae L4 and L5
(Boden, Schimandle, & Hutton, 1995). Animals were assigned into
seven experimental groups with N = 4 in each group as follows: ABC
alone; ABC and ALLO; ABC with 50 μg/ml rhBMP6; ABC with 100
μg/ml rhBMP6; ABC with 200 μg/ml rhBMP6; ABC with 200 μg/ml
rhBMP6 and ALLO; and ABC with 400 μg/ml rhBMP6 and ALLO.
The operationswere carried out under general anaesthesia. Xylazine
(Xylapan®, Vetoquinol, Switzerland) in dose of 5 mg/kg body weight
and Ketamine (Ketaminol® Vetoquinol, Switzerland) in dose of 35
mg/kg body weight were applied intramuscularly. Analgetic ketoprofen
(Ketofen®, Merial, France) in dose of 4 mg/kg body weight was applied
s.c. Prior to iv catheter placement hair was clipped and skin aseptically
prepared. Spinal fusion was carried out in the lumbar region between
L4 and L5 vertebrae. After placing the rabbit in the prone position, a dor-
sal midline skin incision extending from L4 to L7wasmade followed by a
paramedian fascial incision (Boden et al., 1995; Schimandle, Boden, &
Hutton, 1995). An intermuscular plane was established between the
multifidus and longissimus muscle layers using blunt dissection facilitat-
ing exposure of the transverse processes of L5 and L6 as well as the
intertransverse membrane. An electric cauterizer was used as needed
to minimize blood loss. Defects (device was placed between the trans-
verse process in the paraspinal bed bilaterally) were filled with ABC
alone or in combination with ALLO and rhBMP6 according to the
predefined experimental groups. Lateral aspect of transverse processes
were decorticated until bleeding by high speed burr where prepared
ABGS devices were placed. The fascial incisionwas closedwith 4‐0 syn-
thetic glycolide/lactide copolymer absorbable sutures. The aforemen-
tioned procedure was repeated on the contralateral side.
Whereas in the first experiment, decortication of transverse pro-
cesses was performed as an usual procedure in all the operations, ina separate experiment bone, decortication was explored as a contrib-
uting factor to the quality of the spinal fusion (Ishikawa, Shin, Bowen,
& Cummings, 1994). Twelve animals were divided into three groups
with N = 4 in each group as follows: ABC with 100 μg/ml rhBMP6
with decortication, ABC with 100 μg/ml rhBMP6 without decortica-
tion, and ABC with 100 μg/ml rhBMP6 and ALLO without
decortication.
All animals were euthanized 14 weeks after the surgery by using
premedication of 3 mg/kg xylapane and 20 mg/kg ketamine i.m. and
administration of T61 (1 ml/kg) i.v. Ethical principles of the study
ensured compliance with European Directive 2010/63/EU, the Law
on Amendments to Animal Protection Act (Official Gazette 37/13),
the Animal Protection Act (Official Gazette 102/17), Ordinance on
the protection of animals used for scientific purposes (Official Gazette
55/13), FELASA recommendations, and recommendations of the
Ethics Committee School of Medicine, University of Zagreb. During
experiment, no adverse effects have been observed in any of the
experimental groups.
2.5 | Anti‐rhBMP6 antibodies
The presence of anti‐rhBMP6 antibodies was investigated within the
toxicology GLP study on BMP6 biocompatibility, safety, and efficacy,
including biochemical, hematological, gross pathology, and histology
examination carried out in Meditox, Czech Republic, as one aspect of
this study. The toxicology study has been conducted in 30 rabbits
and was approved by Meditox s.r.o. Institutional Animal Care and
Use Committee and the Committee for Animal Protection of the Min-
istry of Health of the Czech Republic (58/2016). New Zealand white
rabbits were used, n = 5/sex/dose level (total of 30 animals). Three
dose groups were administered with 0 (control, ABC alone), 1 mg
(low dose), and 2‐mg rhBMP6/ABC (high dose) per animal with surgi-
cal spinal implantation between vertebrae L4 and L5 as described
above. Transverse processes of L4 and L5 were decorticated with high
speed burr, and area between them was filled with ABC alone (control)
and ABC with 2 × 0.5 mg of rhBMP6 for low‐dose group and ABC with
2 × 1 of mg rhBMP6 for high‐dose group. Application volume for all
groups was 2 × 2.5 ml per animal. Blood samples for antibody assay
were collected during the Week 1 and on Day 21 from the v.
auricularis or v. saphena into tubes without anticoagulant. Samples
were centrifuged (6,000 rpm for 10 min), and the serum split into ali-
quots and immediately frozen at −80°C until analysis.
2.6 | Methods of evaluation
Radiographical images were taken before the surgery and at Weeks 3,
6, 9, and 14 after surgery. X‐ray imaging of lumbar spine segment were
performed using two standard orthogonal views (lateral and dorsoven-
tral). Samples were scanned on Eichermeyer EDR HP (IMD Generators
s. r. l., Italy) X‐ray machine using the 40 kV and 8 mAs with all ioniza-
tion protection protocols respected during the imaging, whereas
images were processed using Agfa CR 30‐X (Agfa, Japan). All obtained
radiographs from rabbit bones were interpreted and scored using a
150 VUKICEVIC ET AL.radiographic grading score system (Lindley et al., 2017) by a surgeon
and a radiologist blinded to the treatment protocol and postoperative
interval.
Micro‐CT detailed analysis of rabbit lumbar spine spanning from L4
to L7 was done using the Sky Scan 1076 micro‐CT device (Hildebrand,
Laib, Muller, Dequeker, & Ruegsegger, 1999). Ex vivo lumbar spine was
scanned at the resolution of 18 μm, 0.5‐mm aluminium filter, 0.5° rota-
tional step, and frame averaging set at 2. Concurrent dataset analysis
of the site of implantation was analysed by CTAn (Sky Scan) software.
The new bone formation and trabecular bone parameters were
depicted throughout the whole area of newly formed bone, as previ-
ously described (Erjavec et al., 2016; Grgurevic et al., 2011).
2.7 | Histology
Explanted rat subcutaneous samples were fixed in 4% formalin for 10
days. After fixation, samples from Days 7 and 14 were decalceinated
using 14% EDTA in 4% formalin solution for 20 days, with solution
change every 2 days. All samples were embedded in paraffin and cut
at 5‐μm slice thickness. To identify progenitor cells present preceding
to and during bone formation, sections were stained with alkaline
phosphatase, and the cell numbers were expressed per mm2 of the
implant area. For measurement of the inflammatory response in the
rat subcutaneous implant model, slices were subjected to analysis of
foreign body giant cells (FBGCs) by H&E staining and acid phosphatase
detection by histochemistry. Number of FBGC was determined on his-
tological sections (three to four samples per group), and on each sam-
ple, FBGCs were counted in three fields (one field = 1 mm2).
Immunohistochemistry of rat subcutaneous implants was performed
using the Mouse and Rabbit specific IHC Detection kit—Micro‐
polymer (Abcam ab236467) with following antibodies: anti‐alkaline
phosphatase, dilution 1:250 (Abcam ab108337); anti‐Sox9, dilution
1:2,000 (Abcam ab185230); and anti‐osteocalcin, 10 μg/ml (Abcam
ab13418).
Muscle free rabbit spine samples were fixed in 4% formalin for 3
weeks, trimmed of soft tissue, and entire bone was embedded in plas-
tic resin (Technovit 7200). Samples were cut at 5‐μm slices with a dia-
mond saw and stained using Masson Goldner Trichrome dye, as
previously described (Krempien, Vukicevic, Vogel, Stavljenic, &
Buchele, 1988; Vukicevic, Krempien, & Stavljenic, 1987). Images were
obtained using Olympus BX51 Epi‐Fluorescence microscope.
2.8 | rhBMP6 immunochemical analyses
Time‐dependent release of rhBMP6 from the ABC plus allograft
in vitro was determined on blood samples from healthy human volun-
teers. Blood was collected from the cubital vein into tubes without
anticoagulants. Upon withdrawal, blood was mixed with allograft (par-
ticle sizes 2–5 or 5–8 mm) and rhBMP6 in two concentrations (62.5 or
125 μg). After the coagulation was completed (60 min), ABC+rhBMP6
plus allograft was rinsed with 1 ml of the basal medium. Each implant
was placed in a Falcon tube containing 3 ml of Dulbecco's modified
Eagle medium. Tubes were incubated at 37°C during 10 days, andthe medium was replaced on Days 1, 3, 6, 8, and 10. The amount of
BMP6 released from the ABC/ALLO/rhBMP6 in the medium was
determined by rhBMP6‐specific ELISA (R&D systems, DY507).
For determination of the presence of anti‐rhBMP6 antibodies in
the serum samples, a previously validated indirect ELISA method was
used. Microtiter plates were coated overnight with 100 ng/ml rhBMP6
diluted in carbonate buffer. Serum samples were diluted in reagent dil-
uent (1% BSA in PBS) to six different dilutions (1:50, 1:100, 1:500,
1:1,000, 1:5,000, and 1:10,000), and biotinylated goat anti‐rabbit IgG
(R&D BAF008, diluted 1:5,000) was used as secondary antibody.
Serum samples from six animals were analysed on the same plate,
and each plate included the negative serum pool diluted at the same
ratio as the study samples. Absorbance was read at 450 nm using
Absorbance Microplate Reader ELx 808TM. Validation cut point value
for each dilution point was determined during the method validation
(Mire‐Sluis et al., 2004). Briefly, 10 samples of rabbit naïve serum were
analysed in dilution series from 1:50 to 1:10,000. The assay cut point
was calculated according to the following formula: mean absorbance +
1.645 × SD, where 1.645 is the 95th percentile of the normal distribu-
tion. Samples with absorbance readings higher than determined cut
point value at particular dilution would be defined as positive.2.9 | Data management
Values are expressed as mean ± SEM or SD as indicated. For statistical
comparison of two samples, a two‐tailed Student t test was used, and
P < .05 was considered significant where indicated. Two‐way analysis
of variance with Duncan's multiple range test was performed to deter-
mine the effect of treatment and time on biochemical and bone repair
parameters. Additional specific data analyses, if applicable, are pre-
sented in figure legends. Analyses were performed by SAS for Win-
dows 9.3 (SAS Inc.).3 | RESULTS
3.1 | Bio‐responsiveness by ABGS in rat
subcutaneous assay
Histology of ALLO/ABC and ALLO/ABC/rhBMP6 implants on Days 7
and 35 is shown in Figure 1a. There was no bone formation in
ALLO/ABC implants (top panel). On the other hand, ABC/ALLO/
rhBMP6 implants showed endochondral bone formation (bottom
panel). In ABC/ALLO/rhBMP6 Day 7 implants, we further confirmed
the newly formed cartilage with histochemical staining for SOX‐9, a
transcription factor for chondrogenesis (Figure S1A,B), and the evi-
dence of new bone formation by alkaline phosphatase (Figure S1C)
and osteocalcin (Figure S1D) staining, markers of osteoblast pheno-
type. The newly formed bone underwent a typical bone remodelling
mediated by osteoclasts as shown on Day 35 implants, where ALLO
particles were replaced by newly formed bone via a creeping substitu-
tion (Figure 1a, bottom panel). The robust osteogenesis was observed
with a gradual resorption of ALLO bone particles, as visualized by
FIGURE 1 Allograft in ABC without and with rhBMP6 following subcutaneous implantation in rats. (a) ABC/ALLO (black arrows) without
rhBMP6 induced formation of fibrotic tissue at Days 7 and 35 without any sign of new bone formation. ABC/ALLO with rhBMP6 induced new
bone formation at Day 7 (yellow arrows) and advanced creeping substitution of ALLO with new bone was observed on Day 35 (blue arrowhead).
(b) Overall micro‐CT analyses of ABC/ALLO implants without and with rhBMP6 are shown in the top row, only ALLO particles are visualized in the
middle row, and the bottom row represents the newly formed bone, image obtained upon subtracting the ALLO particle from overall micro CT.
Note the formation of new bone by 7 days and significant by Day 35 in ABC/ALLO implants that contained rhBMP6. ABC/ALLO alone did not
induce bone either at 7 or 35 days after implantation. (c) Morphometric analysis of ALLO volume in implants on Days 7 and 35 indicating a
significant decrease of ALLO volume and increased of the amount of bone in the presence of rhBMP6. Results are shown as mean ± SD (n = 5). *P <
.05 and **P < .01 versus ALLO (two‐tailed Student's t test). (d) ALLO (white asterisks) when implanted without ABC resulted in recruitment of
numerous foreign body giant cells (FBGC; yellow arrows). (e) ALLO when implanted with ABC showed significantly decreased number of FBGCs. (f)
ALLO when mixed with ABC and rhBMP6 induced endochondral and intramembranous bone formation (green arrowheads) in between ALLO
particles and surrounded by new vasculature (red arrowheads), note absence of FBGCs. (g) Total number of FBGCs from three histological sections
of representative implants. *P < .05 and **P < .01 versus ALLO and ALLO + ABC, respectively; #P < .05 versus ALLO and ALLO/ABC/rhBMP6 (two‐
tailed Student's t test). (h,i) Multinucleated FBGCs stained for acid phosphatase (yellow arrows) in adjacent sections of ALLO alone implants
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in the rat subcutaneous implants were quantified using micro‐CT anal-
ysis for ABC/ALLO and ABC/ALLO/rhBMP6 implants on Days 7 and
35 (Figure 1c).
When implanted in rat subcutaneous sites, ALLO bone particles
induced inflammation and foreign‐body reaction due to high Ca/P
mineral content at ectopic sites by recruiting mononuclear phago-
cytes by Days 1–3 (data not shown), which then fused to form mul-
tinucleated FBGCs by Days 7–14 (Figure 1d). The fusion of
multinucleated FBGCs was significantly reduced when ALLO parti-
cles were formulated with ABC (Figure 1e). In the ABGS implants
that contained ABC/ALLO/rhBMP6, there were even fewer or no
FBGCs, and new endochondral bone formation was observed in
apposition to ALLO particles (Figure 1f). Figure 1g represents the
average number of multinucleated FBGCs counted morphometrically
from three representative histology sections from ALLO, ALLO/ABC,
and ALLO/ABC/rhBMP6 implants. The multinucleated FBGCs cells
recruited by ALLO implants were further characterized by immuno-
histochemistry for acid phosphatase staining, which was reduced by
addition of ABC (Figure 1h,i).
3.2 | Production of ABGS device
The shape and dimension of the produced ABGS implant for use in
rabbit PLF model is presented in Figure 2a. In ABGS/ALLO implants,
the added ALLO particles were distributed uniformly within the
implants, as revealed by X‐ray and micro‐CT analysis. The presence
of ALLO has significantly increased the stiffness and elasticity of
the device and improved compatibility and handling properties as
compared with the implants without ALLO (Figure 2b). About 0.1
to 0.2 g of ALLO particles (74–420 μM) per 0.5 ml of ABC is suffi-
cient to provide the handling rheological properties.
As rhBMP6 is mainly bound to plasma proteins in ABGS
(Grgurevic et al., 2018), the calculated cumulative total release mea-
sured in vitro over 10 days from ABGS was only 3–5% of total
rhBMP6 dose (Figure 2c). Addition of ALLO in different particle sizes
seemed to slightly attribute to more cumulative release. The release
kinetics of rhBMP6 may change at the implant site as the protein is
taken up by the responding cells to trigger endochondral bone differ-
entiation as well as fibrinolysis of ABGS, which does not occur
in vitro. Furthermore, it is noteworthy that there were no anti‐
rhBMP6 antibodies detected in sera of rabbits treated with
ABC/rhBMP6 implants (1 and 2 mg of rhBMP6 per animal) at 3
weeks following implantation (Figure 2d).3.3 | Evaluation of ABGS in rabbit PLF model
The follow‐up of the new bone formation in all experimental groups as
assessed by X‐ray at different time points after surgery is shown in
Figure 3. Figure 4a shows X‐ray, micro‐CT, and gross anatomy photo-
graphs of ABGS without and with ALLO at varying doses of rhBMP6
per ml of ABC as compared with ABC alone and ABC plus ALLO
groups at the end of experiment, 14 weeks after surgery. Bonedecortication of transverse processes was performed in all the groups.
The group that contained rhBMP6 at 50 μg/ml ABC demonstrated
new bone formation but achieved fusion in only two out of four rab-
bits, suggesting that the amount of rhBMP6 might not have been suf-
ficient, whereas rhBMP6 at 100 μg/ml ABC achieved a complete
spinal fusion in all the rabbits. Because ALLO is capable of inducing
inflammation and formation of multinucleated FBGCs, we have formu-
lated ABGS implants with higher amounts of rhBMP6. ABGS/ALLO
that contained 200 μg/ml ABC induced a complete fusion with bone
volume comparable with that of ABGS that had 100 μg/ml ABC with-
out ALLO; however, an increased amount of rhBMP6 to 400 μg/ml
ABC did not further increase the bone volume. In the groups that
had ABC alone or ABC/ALLO, no bone formation was observed and
spine did not fuse. The successfully fused bone by ABGS (ABC/
rhBMP6 or ABC/ALLO/rhBMP6) groups appeared to be compact
and solid (Figure 4a). The contact area between the transverse pro-
cesses and the newly formed bone was indistinguishable and fused
into one continuous bone segment.
Radiographic images of all samples were scored and measurement
of new bone was quantified for bone volume, trabecular number and
trabecular interconnectivity, as determined by micro‐CT analyses and
are presented in Figure 4b–e. ABGS at a dose of 100‐μg rhBMP6
per ml of ABC appears to be the optimal dose, and doubling the dose
does not increase the bone formation parameters. ABGS plus ALLO
implants that contained either 200‐ or 400‐μg rhBMP6 per ml of
ABC resulted in new bone formation comparable with ABGS without
ALLO at 100‐μg rhBMP6 per ml of ABC.
The histology showed that in ABGS implants, the newly formed
bone underwent a new bone formation with a typical remodelling
and osseous integration at the interface in between the newly formed
bone and the native transverse processes (Figure 5). In ABGS contain-
ing ALLO implants, the newly formed bone underwent a rapid bone
remodelling and was fully integrated with ALLO particles, which even-
tually got replaced by creeping substitution. An extended osteoid seam
covered surfaces of newly formed bone with areas of woven bone and
immature osteocytes (Figure 5).
In addition, we examined whether decortication of transverse pro-
cesses is required to achieve a successful fusion. Rabbits were treated
with implants ABC containing 100‐μg rhBMP6 per ml with or without
decortication during the operation procedure. The results show that
two out of four implants did not fuse rabbits without decortication
procedure, whereas four out of four implants have fused in rabbits
upon decortication. We also found ABGS when formulated with ALLO,
three out of three implants have fused in rabbits without decortica-
tion, suggesting that ALLO may facilitate the fusion of transverse pro-
cesses with newly formed bone with or without decortication
(Figure 6).4 | DISCUSSION
In the present study, we demonstrated that an ABGS that contains
rhBMP6 dispersed within ABC, without or with ALLO particles, is
FIGURE 2 The shape and dimension of the produced ABGS implants for use in rabbit PLF model. (a) ABGS implants with allograft prepared for
rabbit (1.5 × 1.0 cm) posterolateral spine fusion experiments; left is gross picture, the centre is X‐ray, and right is micro‐CT. (b) Biomechanical
properties of ABGS were tested using the CUT test for measuring stiffness, elasticity, and strain in implants with various allograft amounts (1–2 g)
per 5 ml of blood. Values are shown as mean ± SEM (n = 4), *P < .05 and **P < .01 (two‐tailed Student's t test) when compared with the implant
without allograft. (c) Cumulative in vitro release of rhBMP6 over 10 days from ABGS expressed as a percent of the total rhBMP6 dose. Results are
presented as individual values from two experiments. (d) Absence of the anti‐rhBMP6 antibodies in rabbit serum was demonstrated by indirect
ELISA method a week before and 3 weeks after surgery. Cut point value was determined during the method validation process. Mean ± SD (n = 10)
of absorbance (A450) values are shown
VUKICEVIC ET AL. 153capable of inducing new bone formation in rat subcutaneous implants
and achieving a fusion in a rabbit spine PLF model. BMP6 was chosen
as a preferred BMP as its binding to Noggin, a natural BMP antagonist
present in abundance in bone, is lesser than other BMPs (Klineberg
et al., 2014; Song et al., 2010; Vukicevic et al., 2014). BMP6 also binds
to most of theTypes I and II BMP receptors and exhibits a high specific
alkaline phosphatase activity in osteoblastic cell cultures (Grgurevic
et al., 2018; Song et al., 2010), hence permitting the use of lower
doses as compared with BMP2 or BMP7. ABC was chosen as a phys-
iological carrier as it suppresses foreign body response, promotes tight
rhBMP6 binding with plasma proteins within the fibrin meshwork,
allows a sustained release of rhBMP6, and avoids generation of anti-
bodies to rhBMP6, thus providing a permissive environment for endo-
chondral bone differentiation. In our previous work (Grgurevic et al.,
2018), we have demonstrated that the use of ABC as a carrier reduced
the immune response when compared with the use of bovine collagen,
as shown by reduced neutrophil accumulation and myeloperoxidase
activity in rat subcutaneous implants. The ALLO particles are added
and distributed uniformly across the ABC to provide adequate biome-
chanical and biocompatible good handling properties.ABGS containing ABC or ABC/ALLO are produced with defined
rheological properties. We observed for the first time that ABC has
an unexpected inherent biological property as it overcomes foreign
body responses elicited by high Ca/P‐containing mineralized matrix
(ALLO) at ectopic sites. When implanted alone, ALLO did not form
bone at subcutaneous (ectopic) site but instead recruited mononu-
clear phagocytes which then fused to form multinucleated FBGCs
to dissolve the mineralized bone matrix implanted at a nonbony site.
On the other hand, ALLO implants when combined with ABC
reduced significantly the formation of multinucleated FBGCs and
with rhBMP6 dispersed within ABC resulted in formation of endo-
chondral bone. It is likely that ABC coated ALLO surface masked
T‐cell recognition, thus suppressing foreign body response locally.
The dose of rhBMP6 required to induce optimal bone formation
are comparable in ABGS with or without ALLO as it binds to ABC
more tightly than to ALLO and released locally in times with the res-
olution of ABC by haemolysis. ABGS induced bone is a dose‐
dependent with an optimal dose of rhBMP6 at 100 μg/ml ABC
and produced a complete fusion between two lumbar transverse
processes in rabbit PLF model.
FIGURE 3 Rabbit spinal fusion (L4–L5) imaged in all groups by X‐ray at Weeks 3, 6, 9, and 14 during the experiment. White arrows indicate new
bone, while yellow arrows indicate allograft particles
FIGURE 4 (a) Rabbit spinal fusion (L4–L5) after treatment with various doses of rhBMP6 without and with ALLO at 14 weeks after surgery, as
visualized by X‐ray (top row), micro‐CT (middle row), and gross anatomy macerated specimen (bottom row). (b) Spinal fusion X‐ray scoring results.
(c–e) Spinal fusion morphometric parameters measured from micro‐CT images. Results are shown as mean ± SD (n = 4). *P < .05 versus negative
control, **P < .05 versus ABC + ALLO (one‐way ANOVA with Tukey post hoc test)
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FIGURE 5 Histology of ABGS implants without and with ALLO harvested at 14 weeks after surgery in rabbit PLF model. Left rows represent
ABGS implants without ALLO: note newly formed bone containing dense trabecular structure with laid‐down osteoid at the surface (black
arrows) and pronounced bone remodelling with numerous blood vessels (yellow arrows). Right rows represent ABGS implants with ALLO: The
newly formed trabeculae is assimilated with ALLO (blue arrows) via creeping substitution and invaded by new blood vessels (yellow arrows)
VUKICEVIC ET AL. 155The newly formed bone in ABGS containing ALLOwas compact and
underwent typical bone remodelling as examined by micro‐CT analysis
and histology, which mimics that of autograft assimilation observed in
orthotropic sites (Gupta, Keshav, & Kumar, 2016) via a creeping substi-
tution. ALLO particles provided better structural stability for ABGS,
compared with ABGS alone, while permitting the migration of bone
forming cells as evidenced by bone formation and ALLO remodelling.
We also examined the contribution of decortication versus no decorti-
cation of transverse processes prior to placing of the implant, and the
results showed that decortication has produced significantly a higher
success rate of spinal fusion than keeping the cortices intact.
RhBMP2 (InFUSE) and rhBMP7 (OP‐1 Putty) have been shown to
induce new bone formation and promote radiographic fusion in PLF
animal models (Boden, Moskovitz, Morone, & Toribitake, 1996; Jenis,
Wheeler, Parazin, & Connolly, 2002; Martin, Boden, Marone, Marone,
& Moskovitz, 1999; Suh et al., 2002; Vukicevic & Sampath, 2017). In
contrast to these studies, we show here that rhBMP6 in ABGS
induced bone formation at lower doses, and the newly formed bone
was restricted to the size and shape of the implants. Although the
use of InFUSE (INFUSE Bone Graft product information: Lumbar,
2002) in conjunction with the LT‐Cage device has been approved for
ALIF procedures in patients with DDD at one level from L2 to S1
(Burkus, Gornet, Dickman, & Zdeblick, 2002), the off‐label use for
anterior cervical fusion in patients has produced unwanted safety
issues that included radiculitis, vertebral body resorption, seroma
and/or haematoma formation, uncontrolled heterotopic ossification,osteolytic erosion, retrograde ejaculation, and concerns of possible
cancer risks (Cahill, McCormick, & Levi, 2015; Wong, Kumar, Jatana,
Ghiselli, & Wong, 2008), which in part may be attributed to the larger
amount of rhBMP2 used in the device (Carragee et al., 2011). Evalua-
tion of rhBMP2 in a porous synthetic slab that is composed of bovine
collagen sponge impregnated with ceramic granules of hydroxyl apa-
tite and tricalcium phosphate in PLF clinical studies demonstrated a
moderate fusion, but a significant number of patients continued to
experience low back pain and leg pain and unwanted adverse events
(Dawson, Bae, Burkus, Stambough, & Glassman, 2009; Dimar et al.,
2009). RhBMP7 as an implantable bone graft substitute also did not
achieve a statistical difference as compared with autograft in a PLF
clinical study (Vaccaro et al., 2004; Vaccaro et al., 2008).
Bovine sourced collagens were used as carriers to deliver BMP2
and BMP7. Bovine Achilles tendon derived acid soluble reconstituted
Type I collagen mesh as in InFUSE (INFUSE Bone Graft product infor-
mation: Lumbar, 2002) or as a slab‐shaped collagen composite with
synthetic ceramics as in Amplify (Executive Summary for P050036
Medtronic's AMPLIFY™ rhBMP‐2 Matrix Orthopedic and Rehabilita-
tion Devices Advisory Panel, 2010) were used to deliver rhBMP2.
Bovine diaphysis bone derived insoluble Type I collagen as particulate
and/or combined with additive carboxymethyl cellulose as injectable
putty were used for rhBMP7/OP1 as in OP1‐Implants (OP‐1 Implant®
product information, 2009) and OP1‐Putty (OP‐1 Putty® product
information, 2009). Sterilization of these bovine sourced collagens by
chemical methods or gamma radiation for clinical uses added
FIGURE 6 Effect of transverse processes
decortication on spinal fusion. The same dose
of rhBMP6 (100 μg/ml) was used. Rabbit
spinal fusion after removal of bone cortex (a),
without decortication (b) and in combination
with allograft (ALLO) particles (c)
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VUKICEVIC ET AL. 157unwanted modifications to collagenous carrier as well (OP‐1 Putty®
product information, 2009). As such, we present here an ABC to serve
as a physiological carrier to deliver rhBMP6 (ABGS) to induce new
bone formation and with allograft (bone particle ALLO) as a compres-
sion resistant matrix to promote osteogenesis in PLF model and mini-
mize adverse events that may be associated with the use of collagen
calcium‐ceramics composite scaffold (Govender, Rampersaud,
Rickards, & Fehlings, 2002).
ABGS containing ABC and rhBMP6 has been evaluated in a First‐
in‐Human randomized, placebo controlled and double blinded Phase I
study in patients with distal radius fracture and in a Phase I/II study
in patients with high tibial osteotomy. ABGS with ALLO devices is cur-
rently being evaluated in a randomized, double blinded, and controlled
Phase II study for posterolateral lumbar interbody fusion against auto-
graft as a comparator.
ACKNOWLEDGEMENTS
This programme was funded by the FP7 Health Program (FP7/2007‐
2013) under grant agreement HEALTH‐F4‐2011‐279239
(Osteogrow), H2020 Health GA 779340 (OSTEOproSPINE), and Euro-
pean Regional Development Fund ‐ Scientific Center of Excellence for
Reproductive and Regenerative Medicine (project “Reproductive and
regenerative medicine ‐ exploration of new platforms and potentials,”
GA KK01.1.1.01.0008 funded by the EU through the ERDF). For ani-
mal studies, we thank to Mirjana Marija Renic and Djurdjica Car for
their excellent technical assistance and to Viktorija Rumenovic for
her contribution in immunohistochemistry analyses and Figure S1.
We thank Charles Cohen (perForm biologics) and David C. Rueger
(Rueger Consulting, Southborough, MA) for their editorial assistance
in the preparation of the manuscript.
AUTHOR CONTRIBUTIONS
The authors and their contributions are as follows: L. G., T. K. S., I. E.,
R. W., S. V., and M. G. (conceptualization); I. E., T. B. N., L. G., S. V., T.
K. S., and M. G. (formal analysis); S. V., L. G., I. E., M. P., T. B. N., N. S.,
M. L., H. C., D. M., R. W., T. K. S., and M. G. (investigation); M. G., M. P.,
L. G., D. M., I. E., and M. L. (methodology); L. G. and D. M. (project
administration); D.M. (supervision); H. C., I. E., N. S., and L. G. (visuali-
zation); S. V., T. K. S., T. B. N., L. G., I. E., and M. G. (writing original
draft).
CONFLICT OF INTEREST
L. G. and S. V. have an issued patent US8197840 and licensed to Gen-
era Research (GR). R. W. is a consultant for Pfizer, Stryker, Takeda,
Depuy Synthes, and Zimmer Biomet; T. K. S. received grants and other
from perForm Biologics during the study; S. V. received grants and
other from (GR) and perForm Biologics during the study. M. G. is a
consultant for Depuy Synthes, Innomed, and Medtronic and receive
royalties from Depuy Synthes and Innomed.
ORCID
Slobodan Vukicevic https://orcid.org/0000-0003-4076-0285REFERENCES
Boden, S. D., Moskovitz, P. A., Morone, M. A., & Toribitake, Y. (1996).
Video‐assisted lateral intertransverse process arthrodesis. Validation
of a new minimally invasive lumbar spinal fusion technique in the rabbit
and nonhuman primate (rhesus) models. Spine (Phila Pa 1976), 21,
2689–2697. https://00024720‐200210000‐00001/00024720‐
200210000‐00001/00007632‐199611150‐00020
Boden, S. D., Schimandle, J. H., & Hutton, W. C. (1995). An experimental
lumbar intertransverse process spinal fusion model. Radiographic, his-
tologic, and biomechanical healing characteristics. Spine (Phila Pa
1976), 20, 412–420.
Bohl, D. D., Webb, M. L., Lukasiewicz, A. M., Samuel, A. M., Basques, B. A.,
Ahn, J., … Grauer, J. N. (2015). Timing of complications after spinal
fusion surgery. Spine (Phila Pa 1976), 40, 1527–1535. https://
10.1097/10.1097/BRS.0000000000001073
Brown, J. V. E, Heirs, M., Higgins, J. P. T., Mannion, R. J., Rodgers, M. A.,
Seneschall, S. C. … Wright, K. (2013). Systematic review and meta‐
analysis of the safety and efficacy of recombinant human bone mor-
phogenetic protein‐2 (rhBMP‐2) in spinal fusion. http://yodayaleedu/
sites/.
Burkus, J. K., Gornet, M. F., Dickman, C. A., & Zdeblick, T. A. (2002). Ante-
rior lumbar interbody fusion using rhBMP‐2 with tapered interbody
cages. Journal of Spinal Disorders & Techniques, 15, 337–349. https://
10.1097/10.1097/00024720‐200210000‐00001
Cahill, K. S., Chi, J. H., Day, A., & Claus, E. B. (2009). Prevalence, complica-
tions, and hospital charges associated with use of bone‐morphogenetic
proteins in spinal fusion procedures. JAMA, 302, 58–66. https://
10.1097/10.1001/jama.2009.956
Cahill, K. S., McCormick, P. C., & Levi, A. D. (2015). A comprehensive
assessment of the risk of bone morphogenetic protein use in spinal
fusion surgery and postoperative cancer diagnosis. Journal of Neurosur-
gery. Spine, 23, 86–93. https://10.1097/10.3171/2014.10.
SPINE14338
Carragee, E. J., Chu, G., Rohatgi, R., Hurwitz, E. L., Weiner, B. K., Yoon, S. T.,
… Kopjar, B. (2013). Cancer risk after use of recombinant bone morpho-
genetic protein‐2 for spinal arthrodesis. The Journal of Bone and Joint
Surgery. American Volume, 95, 1537–1545. https://10.1097/10.2106/
JBJS.L.01483
Carragee, E. J., Hurwitz, E. L., & Weiner, B. K. (2011). A critical review of
recombinant human bone morphogenetic protein‐2 trials in spinal sur-
gery: Emerging safety concerns and lessons learned. The Spine Journal,
11, 471–491. https://10.1097/10.1016/j.spinee.2011.04.023
Dawson, E., Bae, H. W., Burkus, J. K., Stambough, J. L., & Glassman, S. D.
(2009). Recombinant human bone morphogenetic protein‐2 on an
absorbable collagen sponge with an osteoconductive bulking agent in
posterolateral arthrodesis with instrumentation. A prospective random-
ized trial. The Journal of Bone and Joint Surgery. American Volume, 91,
1604–1613. https://10.1097/10.2106/JBJS.G.01157
Diebo, B. G., Passias, P. G., Marascalchi, B. J., Jalai, C. M., Worley, N. J.,
Errico, T. J., & Lafage, V. (2015). Primary versus revision surgery in
the setting of adult spinal deformity: A nationwide study on 10,912
patients. Spine (Phila Pa 1976), 40, 1674–1680. https://10.1097/
10.1097/BRS.0000000000001114
Dimar, J. R. 2nd, Glassman, S. D., Burkus, J. K., Pryor, P. W., Hardacker, J.
W., & Carreon, L. Y. (2009). Clinical and radiographic analysis of an opti-
mized rhBMP‐2 formulation as an autograft replacement in
posterolateral lumbar spine arthrodesis. The Journal of Bone and Joint
Surgery. American Volume, 91, 1377–1386. https://10.1097/10.2106/
JBJS.H.00200
Erjavec, I., Bordukalo‐Niksic, T., Brkljacic, J., Grcevic, D., Mokrovic, G.,
Kesic, M., … Vukicevic, S. (2016). Constitutively elevated blood
158 VUKICEVIC ET AL.serotonin is associated with bone loss and type 2 diabetes in rats. PLoS
One, 11, e0150102. https://10.1097/10.1371/journal.pone.0150102
Executive Summary for P050036 Medtronic's AMPLIFY™ rhBMP‐2 Matrix
Orthopedic and Rehabilitation Devices Advisory Panel. (2010). Food
and Drug Administration.
Fernyhough, J. C., Schimandle, J. J., Weigel, M. C., Edwards, C. C., & Levine,
A. M. (1992). Chronic donor site pain complicating bone graft harvest-
ing from the posterior iliac crest for spinal fusion. Spine (Phila Pa 1976),
17, 1474–1480.
Fu, R., Selph, S., McDonagh, M., Peterson, K., Tiwari, A., Chou, R., &
Helfand, M. (2013). Effectiveness and harms of recombinant human
bone morphogenetic protein‐2 in spine fusion: A systematic review
and meta‐analysis. Annals of Internal Medicine, 158, 890–902. https://
10.1097/10.7326/0003‐4819‐158‐12‐201306180‐00006
Garcia‐Gareta, E., Coathup, M. J., & Blunn, G. W. (2015). Osteoinduction of
bone grafting materials for bone repair and regeneration. Bone, 81,
112–121. https://10.1097/10.1016/j.bone.2015.07.007
Glassman, S. D., Carreon, L. Y., Djurasovic, M., Campbell, M. J., Puno, R. M.,
Johnson, J. R., & Dimar, J. R. (2008). RhBMP‐2 versus iliac crest bone
graft for lumbar spine fusion: A randomized, controlled trial in patients
over sixty years of age. Spine (Phila Pa 1976), 33, 2843–2849. https://
10.1097/10.1097/BRS.0b013e318190705d
Goldberg, V. M., & Stevenson, S. (1987). Natural history of autografts and
allografts. Clinical Orthopaedics and Related Research, 225, 7–16.
Govender, P. V., Rampersaud, Y. R., Rickards, L., & Fehlings, M. G. (2002).
Use of osteogenic protein‐1 in spinal fusion: Literature review and pre-
liminary results in a prospective series of high‐risk cases. Neurosurgical
Focus, 13, 1, e4–6.
Grgurevic, L., Macek, B., Mercep, M., Jelic, M., Smoljanovic, T., Erjavec, I., …
Vukicevic, S. (2011). Bone morphogenetic protein (BMP)1‐3 enhances
bone repair. Biochemical and Biophysical Research Communications,
408, 25–31. https://10.1097/10.1016/j.bbrc.2011.03.109
Grgurevic, L., Oppermann, H., Pecin, M., Erjavec, I., Capak, H., Pauk, M., …
Vukicevic, S. (2018). Recombinant human bone morphogenetic protein
6 delivered within autologous blood coagulum restores critical size seg-
mental defects of ulna in rabbits. Journal of Bone and Mineral Research
Plus, 3, e10085. https://10.1097/10.1002/jbm4.10085.10.1002/
jbm4.10085
Gupta, A. K., Keshav, K., & Kumar, P. (2016). Decalcified allograft in repair
of lytic lesions of bone: A study to evolve bone bank in developing
countries. Indian Journal of Orthopaedics, 50, 427–433. https://
10.1097/10.4103/0019‐5413.185609
Gupta, S., Mohan, V., & Gupta, M. C. (2017). Biology of spine fusion and
application of osteobiologics in spine surgery. In S. Vukicevic, & T. K.
Sampath (Eds.), Bone Morphogenetic Proteins: Systems Biology Regula-
tors. Cham: Springer International Publishing.
Hildebrand, T., Laib, A., Muller, R., Dequeker, J., & Ruegsegger, P. (1999).
Direct three‐dimensional morphometric analysis of human cancellous
bone: Microstructural data from spine, femur, iliac crest, and calcaneus.
Journal of Bone and Mineral Research, 14, 1167–1174. https://10.1097/
10.1359/jbmr.1999.14.7.1167
Hsu, W. K. (2014). Recombinant human bone morphogenetic protein‐2 in
spine surgery. Journal of Bone and Joint Surgery Review, 2, 1. https://
10.1097/10.2106/JBJS.RVW.M.00107
INFUSE Bone Graft product information: Lumbar. (2002). Medtronic
Sofamor Danek USA, Inc. Available from: www.accessdata.fda.gov/
cdrh_docs/pdf/P000058c.pdf.
Ishikawa, S., Shin, H. D., Bowen, J. R., & Cummings, R. J. (1994). Is it neces-
sary to decorticate segmentally instrumented spines to achieve fusion?
Spine (Phila Pa 1976), 19, 1686–1690.Jain, A., Hassanzadeh, H., Strike, S. A., Skolasky, R. L., & Riley, L. H. 3rd.
(2014). rhBMP use in cervical spine surgery: Associated factors and
in‐hospital complications. The Journal of Bone and Joint Surgery. Ameri-
can Volume, 96, 617–623. https://10.1097/10.2106/JBJS.M.00666
Jenis, L. G., Wheeler, D., Parazin, S. J., & Connolly, R. J. (2002). The effect
of osteogenic protein‐1 in instrumented and noninstrumented postero-
lateral fusion in rabbits. The Spine Journal, 2, 173–178.
Klineberg, E., Haudenschild, D. R., Snow, K. D., Garitty, S., Christiansen, B.
A., Acharya, C., … Gupta, M. C. (2014). The effect of noggin interfer-
ence in a rabbit posterolateral spinal fusion model. European Spine
Journal, 23, 2385–2392. https://10.1097/10.1007/s00586‐014‐
3252‐8
Krempien, B., Vukicevic, S., Vogel, M., Stavljenic, A., & Buchele, R. (1988).
Cellular basis of inflammation‐induced osteopenia in growing rats. Jour-
nal of Bone and Mineral Research, 3, 573–582. https://10.1097/
10.1002/jbmr.5650030514
Lindley, E. M., Barton, C., Blount, T., Burger, E. L., Cain, C. M., Seim, H. B.
3rd, … Patel, V. V. (2017). An analysis of spine fusion outcomes in
sheep pre‐clinical models. European Spine Journal, 26, 228–239.
https://10.1097/10.1007/s00586‐016‐4544‐y
Liu, X., Wang, Y., Qiu, G., Weng, X., & Yu, B. (2014). A systematic review
with meta‐analysis of posterior interbody fusion versus posterolateral
fusion in lumbar spondylolisthesis. European Spine Journal, 23, 43–56.
Martin, G. J. Jr., Boden, S. D., Marone, M. A., Marone, M. A., & Moskovitz,
P. A. (1999). Posterolateral intertransverse process spinal arthrodesis
with rhBMP‐2 in a nonhuman primate: Important lessons learned
regarding dose, carrier, and safety. Journal of Spinal Disorders, 12,
179–186.
McAnany, S. J., Baird, E. O., Qureshi, S. A., Hecht, A. C., Heller, J. G., &
Anderson, P. A. (2016). Posterolateral fusion versus interbody fusion
for degenerative spondylolisthesis: A systematic review and meta‐
analysis. Spine (Phila Pa 1976), 41, E1408–E1414. https://10.1097/
10.1097/BRS.0000000000001638
Mire‐Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M.,
… Zuckerman, L. A. (2004). Recommendations for the design and opti-
mization of immunoassays used in the detection of host antibodies
against biotechnology products. Journal of Immunological Methods,
289, 1–16. https://10.1097/10.1016/j.jim.2004.06.002
Mobbs, R. J., Loganathan, A., Yeung, V., & Rao, P. J. (2013). Indications for
anterior lumbar interbody fusion. Orthopaedic Surgery, 5, 153–163.
https://10.1097/10.1111/os.12048
Mobbs, R. J., Phan, K., Malham, G., Seex, K., & Rao, P. J. (2015). Lumbar
interbody fusion: Techniques, indications and comparison of interbody
fusion options including PLIF, TLIF, MI‐TLIF, OLIF/ATP, LLIF and ALIF.
Journal of Spine Surgery, 1, 2–18. https://10.1097/10.3978/j.issn.2414‐
469X.2015.10.05
Murphy, M. E., McCutcheon, B. A., Grauberger, J., Shepherd, D., Maloney,
P. R., Rinaldo, L., … Bydon, M. (2019). Allograft versus autograft in cer-
vical and lumbar spinal fusions: An examination of operative time,
length of stay, surgical site infection, and blood transfusions. Journal
of Neurosurgical Sciences, 63, 11–18.
OP‐1 Implant® product information. Stryker Biotech. (2009). Available
from: www.stryker.com/stellent/groups/public/documents/web_prod/
126737.pdf.
OP‐1 Putty® product information. (2009). Stryker Biotech. Available from:
www.stryker.com/stellent/groups/public/documents/web_prod/
127024.pdf.
Riederman, B. D., Butler, B. A., Lawton, C. D., Rosenthal, B. D., Balderama,
E. S., & Bernstein, A. J. (2017). Recombinant human bone morphoge-
netic protein‐2 versus iliac crest bone graft in anterior cervical
discectomy and fusion: Dysphagia and dysphonia rates in the early
VUKICEVIC ET AL. 159postoperative period with review of the literature. Journal of Clinical
Neuroscience, 44, 180–183. https://10.1097/10.1016/j.
jocn.2017.06.034
Sampath, T. K., & Reddi, A. H. (1981). Dissociative extraction and reconsti-
tution of extracellular matrix components involved in local bone
differentiation. Proceedings of the National Academy of Sciences of the
United States of America, 78, 7599–7603. https://10.1097/10.1073/
pnas.78.12.7599
Schimandle, J. H., Boden, S. D., & Hutton, W. C. (1995). Experimental spinal
fusion with recombinant human bone morphogenetic protein‐2. Spine
(Phila Pa 1976), 20, 1326–1337.
Simmonds, M. C., Brown, J. V., Heirs, M. K., Higgins, J. P., Mannion, R. J.,
Rodgers, M. A., & Stewart, L. A. (2013). Safety and effectiveness of
recombinant human bone morphogenetic protein‐2 for spinal fusion:
A meta‐analysis of individual‐participant data. Annals of Internal Medi-
cine, 158, 877–889. https://10.1097/10.7326/0003‐4819‐158‐12‐
201306180‐00005
Song, K., Krause, C., Shi, S., Patterson, M., Suto, R., Grgurevic, L., … Alaoui‐
Ismaili, M. H. (2010). Identification of a key residue mediating bone
morphogenetic protein (BMP)‐6 resistance to noggin inhibition allows
for engineered BMPs with superior agonist activity. The Journal of Bio-
logical Chemistry, 285, 12169–12180. https://10.1097/10.1074/jbc.
M109.087197
Suh, D. Y., Boden, S. D., Louis‐Ugbo, J., Mayr, M., Murakami, H., Kim, H. S.,
… Hutton, W. C. (2002). Delivery of recombinant human bone morpho-
genetic protein‐2 using a compression‐resistant matrix in posterolateral
spine fusion in the rabbit and in the non‐human primate. Spine (Phila Pa
1976), 27, 353–360.
Tilkeridis, K., Touzopoulos, P., Ververidis, A., Christodoulou, S., Kazakos, K.,
& Drosos, G. I. (2014). Use of demineralized bone matrix in spinal
fusion. World Journal of Orthopedics, 5, 30–37. https://10.1097/
10.5312/wjo.v5.i1.30
Tomford, W. W. (2000). Bone allografts: Past, present and future. Cell and
Tissue Banking, 1, 105–109. https://10.1097/10.1023/
A:1010158731885
Vaccaro, A. R., Lawrence, J. P., Patel, T., Katz, L. D., Anderson, D. G.,
Fischgrund, J. S., … Wong, D. (2008). The safety and efficacy of OP‐1
(rhBMP‐7) as a replacement for iliac crest autograft in posterolateral
lumbar arthrodesis: A long‐term (>4 years) pivotal study. Spine (Phila
Pa 1976), 33, 2850–2862. https://10.1097/10.1097/
BRS.0b013e31818a314d
Vaccaro, A. R., Patel, T., Fischgrund, J., Anderson, D. G., Truumees, E.,
Herkowitz, H. N., … McCulloch, J. A. (2004). A pilot study evaluatingthe safety and efficacy of OP‐1 Putty (rhBMP‐7) as a replacement for
iliac crest autograft in posterolateral lumbar arthrodesis for degenera-
tive spondylolisthesis. Spine (Phila Pa 1976), 29, 1885–1892.
Vukicevic, S., Krempien, B., & Stavljenic, A. (1987). Effects of 1 alpha,25‐
and 24R,25‐dihydroxyvitamin D3 on aluminum‐induced rickets in
growing uremic rats. Journal of Bone and Mineral Research, 2,
533–545. https://10.1097/10.1002/jbmr.5650020610
Vukicevic, S., Oppermann, H., Verbanac, D., Jankolija, M., Popek, I., Curak,
J., … Grgurevic, L. (2014). The clinical use of bone morphogenetic pro-
teins revisited: A novel biocompatible carrier device OSTEOGROW for
bone healing. International Orthopaedics, 38, 635–647. https://
10.1097/10.1007/s00264‐013‐2201‐1
Vukicevic, S., & Sampath, T. K. (2017). Bone morphogenetic proteins: Systems
biology regulators (1st ed.). Cham: Springer International Publishing.
Wong, D. A., Kumar, A., Jatana, S., Ghiselli, G., & Wong, K. (2008). Neuro-
logic impairment from ectopic bone in the lumbar canal: A potential
complication of off‐label PLIF/TLIF use of bone morphogenetic
protein‐2 (BMP‐2). The Spine Journal, 8, 1011–1018. https://10.1097/
10.1016/j.spinee.2007.06.014
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. A‐D. Histology of rat subcutaneous implants stained for
cartilage and bone markers on day 7. A‐B. ABC/ALLO/rhBMP6
implants stained for SOX‐9, the marker for chondrocytes (arrows). C.
ABC/ALLO/rhBMP6 implants stained for alkaline phosphatase. D.
ABC/ALLO/rhBMP6 implants stained for osteocalcin. Arrows indicate
osteoprogenitor cells.
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